Yiti Medical

Shenzhen Yiti Medical Technology Co., Ltd. (referred to as "Yiti Medical" or the "Company") is a wholly-owned subsidiary of Zhongzhu Holdings (stock code 600568). It is a tumor ecological chain platform company integrating tumor equipment, tumor drugs, tumor centers, tumor hospitals, and tumor internet big data, committed to becoming the * of the entire tumor industry chain. The company has formed a network of branches covering the whole country with Shenzhen, Xi'an, and Beijing as its three major centers. The company is a high-tech enterprise and a national Class III medical device manufacturer, and is a key independent innovation enterprise in Shenzhen. At present, the company has formed four major product lines of "radiotherapy, hyperthermia, phototherapy, and ultrasonic diagnosis" and a nationwide sales network, with more than 80 patent applications. All products have independent intellectual property rights, and multiple medical devices are at the leading level internationally or in the Asia-Pacific region, filling multiple gaps at home and abroad. The company is making great strides in the field of tumor drugs and has now entered the field of anti-cancer gene therapy drugs. Among them, the national Class I new drug "recombinant human endostatin adenovirus injection" won the gold award of the 10th China Invention Patent. In the future, it will increase efforts in the research and development of new anti-tumor drugs, acquire suitable new drug targets, and enrich the tumor drug series. Relying on advantages in equipment, technology, experts, management, and brand marketing, the company has built characteristic tumor specialty departments in more than 40 hospitals across the country, invested in more than 100 large and medium-sized equipment, and has a nationwide resource of 100 tumor experts, providing diagnosis, treatment, and rehabilitation services for nearly 200,000 tumor patients, forming a domestic tumor hospital entity network of considerable scale. Based on the foundation of the tumor industry, the company takes investing in tumor specialty hospitals as its core, with capital and the internet as its two wings, to build China's * authoritative tumor technology service platform, build China's most widely distributed tumor hospital entity network, and establish China's largest tumor treatment and rehabilitation database. In the future, Yiti Medical will focus on the entire industry chain of tumor screening, diagnosis, prevention, treatment, and rehabilitation, striving to build a medical enterprise with a market value of hundreds of billions and construct a complete tumor medical service ecosystem.